peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Financial reports

2024Press releaseReportPresentationWebcastTranscriptXBRL

18 Apr 2024

Interim report January-March 2024

Press release
Report
Presentation
Casting
Transcript
Coffee and notepad

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.
Investor Relations

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709 298 269

Email: klaus.sindahl@hansabiopharma.com